Thus, CBP/p300 inhibitors may have broader effects on signaling pathways than AR antagonists and the anti-proliferative effects of novel CBP/p300 inhibitors in PCa may not be fully attributable to their inhibition of AR. The gene discussed is EP300; the disease is posterior cortical atrophy.